A phase II, randomized, double blind study to evaluate the efficacy and safety of AMY109 in women with endometriosis
Latest Information Update: 03 Oct 2024
At a glance
- Drugs AMY 109 (Primary) ; Desogestrel (Primary)
- Indications Endometriosis
- Focus Therapeutic Use
- Acronyms ACERS
- Sponsors Chugai Pharmaceutical
Most Recent Events
- 25 Apr 2024 Recruitment completion is expected on 31/07/2025 according to ISRCTN Clinical Trials Registry Record.
- 25 Apr 2024 Planned number of patients changed from 80 to 120.
- 27 Jul 2023 Planned number of patients changed from 63 to 80.